Skip to content

Linked-Color Imaging Versus Indigo Carmine Pump Spraying on the Colorectal Adenoma Detection Rate

Linked-Color Imaging Versus Indigo Carmine Pump Spraying on the Colorectal Adenoma Detection Rate: a Prospective , Randomized Controlled, Non-inferiority Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06961149
Enrollment
352
Registered
2025-05-07
Start date
2025-04-08
Completion date
2026-04-01
Last updated
2025-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma Detection Rate, Adenomatous Polyps, Chromoendoscopy, Colonic Polyps, Colorectal Neoplasms

Keywords

Adenoma Detection Rate, Linked-color imaging, Chromoendoscopy, Colonoscopy, Indigo Carmine

Brief summary

Detection and removal of polyps during colonoscopy is crucial for the prevention of colorectal cancer. Indigo carmine spraying up to the colonic mucosa could probably increase the adenoma detection rate, but considering the long withdrawal time of the endoscope and the resulting increase in time and cost. Linked-color imaging (LCI) is a newly developed image-enhanced endoscopy technology. It relies on wave length optimization of three colors (red, green, and blue) to make the lesions appear fuller. LCI improves the visibility of colorectal adenomas and polyps and may increase the detection rate of lesions. In order to explore the clinical application value of Linked-color imaging endoscopy, we performed a prospective, randomized controlled trial to compare adenoma detection rate of Linked-color imaging endoscopy and indigo carmine chromoendoscopy.

Detailed description

If patients scheduled for colonoscopy meet the inclusion criteria but not the exclusion criteria, participants will be recruited to the study and randomized to one of two groups. Group allocation was revealed to endoscopists upon confirmation of cecal intubation. participants in Group A (treatment group) will undergo colonoscopy with LCI. participants in Group B (control group) will undergo spraying indigo carmine solution during withdrawal process. Any lesions found during the procedure will be removed and sent for pathological examination. The investigator will record the participants' general information (such as gender, age, symptoms, body mass index,etc.), colonoscopy data (such as duration etc.), and lesion characteristics (such as location, morphology, histopathological classification, etc.). All data were analyzed according to the ITT analysis, and the PP analysis was performed for all outcomes. Continuous variables were presented as means ± standard deviation (SD), and compared using Independent Samples t test. Categorical variables were expressed as frequency counts (percentages) and analyzed using Pearson's chi-square test or the Fisher exact test. Statistical analyses were performed using SPSS 27.0. Statistical significance was defined as P \< 0.05.

Interventions

PROCEDUREChromoendoscopy with indigo carmine solution spray

Patients will undergo chromoendoscopy with spraying indigo carmine.

PROCEDURELinked-color imaging endoscopy

Patients will undergo Linked-color imaging endoscopy.

Sponsors

Shandong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Age between 45 and 85 years 2. Patients with a history of colorectal adenoma 3. Patients whose first-degree relatives have a history of colorectal cancer or colorectal adenoma 4. Patients with gastrointestinal symptoms (abdominal pain, bloody stool, chronic diarrhea or constipation, Unexplained anemia or weight loss; 5. Patients with positive Fecal Immunochemical Test

Exclusion criteria

1. Patients with pregnancy, inflammatory bowel disease, familial adenomatosis polyposis, suspected CRC; intestinal obstruction, coagulopathy 2. Patients with aspirin, clopidogrel or other anticoagulants/ antiplatelet drugs intake within 7 days 3. Patents previous colorectal resection 4. Patients with failed cecal intubation 5. Patients with inadequate bowel preparation quality (BBPS≤5) 6. Patients who refuse to participate or to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
adenoma detection rate(ADR)Periproceduraladenoma detection rate (ADR) defined as the percentage of patients with at least one histologically confirmed adenomatous polyp detected and resected during colonoscopy.

Secondary

MeasureTime frameDescription
detected rate of different lesionsPeriproceduraldetected rate of different lesions(advanced adenoma, sessile serrated lesion) adenoma per colonoscopy (APC) withdrawal time adverse event rates

Countries

China

Contacts

Primary ContactRui Ji MD PHD
qljirui@email.sdu.edu.cn+86-18560086103
Backup ContactRui Ji MD PHD, +86-18560086103
qljirui@email.sdu.edu.cn

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026